SCHEMBL11297042

SCHEMBL11297042

CNC(=O)c1cccc(Cn2c(=O)[nH]s/c2=N\c2ccc(C)c(Cl)c2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 3/20 0.44
FEN1 P39748 1/20 0.42
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
PARP1 P09874 1/20 0.38
YTHDC1 Q96MU7 1/20 0.38
ALDH1A1 P00352 4/20 0.36
HPGD P15428 3/20 0.36
KDM4E B2RXH2 3/20 0.36
MAPT P10636 3/20 0.36
CYP2C9 P11712 1/20 0.36
RECQL P46063 1/20 0.36
DPP4 P27487 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MRGPRX4 Q96LA9 1/20 0.36
KMT2A Q03164 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
LMNA P02545 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18950493 0.93 FEN1 (0.44) BRD4FEN1HDAC8HDAC6YTHDC1
SCHEMBL17461562 0.88 BRD4 (0.41) BRD4FEN1HDAC8HDAC6YTHDC1
SCHEMBL11297037 0.82 KDM4E (0.41) ALDH1A1HPGDKDM4EMAPTSMN1; SMN2
SCHEMBL11297046 0.80 GRIN1 (0.40) BRD4FEN1MAPTKMT2A
SCHEMBL11298571 0.80 CCR2 (0.39) ALDH1A1KDM4EMAPTSMN1; SMN2KMT2A
SCHEMBL11297623 0.76 MAPT (0.44) ALDH1A1KDM4EMAPTSMN1; SMN2KMT2A
SCHEMBL11300105 0.75 ADORA2B (0.41) ALDH1A1KDM4EMAPTSMN1; SMN2KMT2A
SCHEMBL11297039 0.74 RGS4 (0.44) ALDH1A1HPGDKDM4EMAPTSMN1; SMN2
SCHEMBL1051365 0.73 IDO1 (0.40) FEN1ALDH1A1HPGDKDM4EMAPT
SCHEMBL1051364 0.73 IDO1 (0.40) FEN1ALDH1A1HPGDKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9675596-B2 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer BALTIC BIO AB (SE) 2017-06-13 US disclosed
US-20160128993-A1 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER BALTICGRUPPEN BIO AB (SE) 2016-05-12 US disclosed
US-9162994-B2 1,2,4-thiazoloidin-3-one derivatives and their use in the treatment of cancer BETAGENON AB (SE) 2015-10-20 US disclosed
US-20120183537-A1 1,2,4-THIAZOLOIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER BETAGENON AB 2012-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160128993-A1 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER HCCS, CCND3, MTNR1A BRD4 131/4885FEN1 3425/4885HDAC8 1834/4885
US-20120183537-A1 1,2,4-THIAZOLOIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER HCCS, CCND3, MTNR1A BRD4 209/4885FEN1 2804/4885HDAC8 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.